A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada
暂无分享,去创建一个
B. Gazzard | C. Leen | B. Yip | M. Wainberg | D. Pillay | A. Winston | C. Sabin | A. Burchell | A. Phillips | F. Lampe | M. Youle | M. Johnson | C. Archibald | J. Weber | J. Ainsworth | M. Cotterchio | T. Antoniou | M. Loutfy | L. Szadkowski | S. Walmsley | M. Gompels | L. Campbell | F. Ibrahim | C. Orkin | F. Post | J. Anderson | M. Nelson | N. Perry | I. Williams | Claire L. Allen | A. Rachlis | S. Sanche | A. Schwenk | C. Liddy | A. Bayoumi | B. Nosyk | S. Johnston | M. Harris | A. Babiker | D. Chadwick | A. Lewszuk | J. Montaner | D. Dunn | D. Corsi | C. Tsoukas | C. Cooper | D. Churchill | F. Martin | P. Hay | M. Smieja | S. Mandalia | M. Hull | A. Wong | Colette Smith | M. Sachikonye | A. Palfreeman | C. Atkinson | P. Phillips | J. Walsh | M. Fisher | V. Delpech | H. Samji | A. Palmer | A. Cescon | V. Lima | S. Guillemi | R. Gilson | D. Asboe | A. Thornton | C. Wood | T. Hill | E. Youssef | Deborah Kelly | David M Moore | R. Masching | J. Zhu | N. Machouf | C. Goldsmith | P. Richard Harrigan | Sean R. Hosein | S. Patterson | B. Trottier | Ken Clement | Monique Doolittle-Romas | L. Edmiston | Brian Huskins | Jerry Lawless | Douglas Lee | Stephen Tattle | A. Zahirieh | S. Calvez | G. Colley | Jason Chia | L. Gilbert | N. Gataric | L. Light | David Mackie | C. Pexos | S. Shurgold | J. Younger | F. Ramzan | David M. Moore | C. Chaloner | A. Wilson | J. Hand | S. Kegg | S. Jose | S. Huntington | N. Brima | J. Raboud | S. Hutchinson | Chris Taylor | R. Hogg | R. Trevelion | S. Morris | M. Carder | E. Ding | R. Everett | M. Klein | SB Rourke | Alia Leslie | J. Wong | S. Allan | J. Pritchard | A. Tariq | A. Glabay | S. Tilbury | H. Korat | Z. Gleisner | R. Tsintas | N. Mackie | J. Lynch | C. de Souza | S. Munshi | Sheila Miller | Sue Allan | K. Memon | E. Cope | J. Gibson | P. Main | M. Dhillon | S. Russell-Sharpe | A. Harte | S. Clay | H. Spencer | Ron Jones | S. Cumming | D. Kelly | S. Rourke | S. Johnston | S. Russell‐Sharpe
[1] A. Thornton. Viral hepatitis and HIV co-infection in the UK Collaborative HIV cohort (UK CHIC) study , 2015 .
[2] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[3] R. Salamon,et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.
[4] R. Hogg,et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada , 2015, BMC Infectious Diseases.
[5] Jean-Guy Baril. La thérapie antirétrovirale pour les adultes infectés par le VIH. Version résumée : guide pour les professionnels de la santé du Québec / comité de rédaction, Dr Jean-Guy Baril [et 11 autres] , 2015 .
[6] A. Pozniak,et al. Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points , 2014, Journal of the International AIDS Society.
[7] J. Sterne,et al. Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] C. Leen,et al. British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) , 2014, HIV medicine.
[9] Jennifer F Hoy,et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.
[10] James J. Goedert,et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.
[11] J. Sterne,et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. , 2012, International journal of epidemiology.
[12] R. Hogg,et al. Disparities in the Burden of HIV/AIDS in Canada , 2012, PloS one.
[13] C. Leen,et al. 7.0 Managing virological failure , 2012, HIV medicine.
[14] Huldrych F. Günthard,et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.
[15] N. Ford,et al. Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda , 2011, Annals of Internal Medicine.
[16] Curtis Cooper,et al. Cohort profile: the Canadian Observational Cohort collaboration. , 2011, International journal of epidemiology.
[17] L. D. Saunders,et al. All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use. , 2011, Canadian journal of public health = Revue canadienne de sante publique.
[18] Ross J. Harris,et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] K. Covinsky,et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers , 2010, HIV medicine.
[20] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[21] S. Jaffar,et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda , 2009, BMC public health.
[22] B. Thiers. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2009 .
[23] Jeffrey N. Martin,et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. , 2008, JAMA.
[24] B. Gazzard. British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.
[25] C. Archibald,et al. Estimates of HIV prevalence and incidence in Canada, 2005. , 2006, Canada communicable disease report = Releve des maladies transmissibles au Canada.
[26] P. Morlat,et al. Number of deaths among HIV-infected adults in France in 2000, three-source capture–recapture estimation , 2006, Epidemiology and Infection.
[27] J. Sterne,et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.
[28] A. Huitema,et al. Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily , 2005, HIV medicine.
[29] Kholoud Porter,et al. The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study , 2004, HIV medicine.
[30] O. Kirk,et al. Modelling the 3‐year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) study , 2003, HIV medicine.
[31] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[32] Bg Gazzard and. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.
[33] M. Schechter,et al. Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users , 2001, Journal of acquired immune deficiency syndromes.
[34] British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy , 2000 .
[35] M A Fischl,et al. Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .
[36] John W. Mellors,et al. Panel on Clinical Practices for Treatment of HIV Infection , 2000 .
[37] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[38] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[39] J. Bartlett,et al. Major controversies in the DHHS guidelines for use of antiretroviral agents in HIV-infected adults. Department of Health and Human Services. , 1998, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.